[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-436534-105":59,"doc-detail-436534-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","risk-analysis-of-subsequent-therapies-after-first-line-chemotherapy-in-advanced-testicular-cancer-patients","Risk analysis of subsequent therapies after first-line chemotherapy in advanced testicular cancer patients","","Retrospective real-world study evaluates predictors of subsequent salvage treatments in advanced testicular cancer after first-line chemotherapy. Advanced patients treated between January 2002 and December 2020 were analyzed by associations between baseline characteristics and clinical outcomes. Among 68 patients, chemotherapy-only cases showed better prognostic risk profiles than the second-line therapy group. Serum tumor marker stage 2–3 independently increased risk of subsequent therapy and was linked to survival differences. Findings support risk stratification to guide clinical decisions.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/risk-analysis-of-subsequent-therapies-after-first-line-chemotherapy-in-advanced-testicular-cancer-patients/436534/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/risk-analysis-of-subsequent-therapies-after-first-line-chemotherapy-in-advanced-testicular-cancer-patients/436534.png","ImageObject",300,407,{"name":92,"@type":93},"Damian","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study objective?","Question",{"text":112,"@type":113},"To analyze risk factors for the need for subsequent (salvage) therapies after first-line chemotherapy in advanced testicular cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and analyzed?",{"text":117,"@type":113},"Advanced testicular cancer patients who received first-line chemotherapy between January 2002 and December 2020 were retrospectively analyzed, assessing associations between baseline characteristics and clinical outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factor was independently associated with the risk of subsequent therapy?",{"text":121,"@type":113},"Serum tumor marker stage 2–3 showed an independent association with the risk of subsequent therapy (HR = 33.13, p = 0.007).",{"name":123,"@type":110,"acceptedAnswer":124},"What do the results suggest for clinical decision-making?",{"text":125,"@type":113},"The predictive role of serum tumor marker stage 2–3 can facilitate clinical decision-making during testicular cancer treatment planning and follow-up.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},436534,1790961663,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},137451208677,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","J Chin MedAssoc  \nOriginal article  \nRisk analysis of subsequent therapies after firstline chemotherapy in advanced testicular cancer patients  \nTsung-Han Yena, Shian-Shiang Wanga,b,c, Cheng-Kuang Yanga, Kevin Lua, Chuan-Shu Chena,b, Chen-Li Chenga,b, Sheng-Chun Hunga,b, Kun-Yuan Chiua,c,d, Chun Pen Chene, Chi-Rei Yangf,* , Jian-Ri Lia,b,d,g,h,*  \naDivision of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, ROC; bInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC; cDepartment of Applied Chemistry, National Chi Nan University, Nantou, Taiwan, ROC; dDepartment of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan, ROC; eDepartment of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, ROC; fDepartment of Urology, China Medical University Hospital, Taichung, Taiwan, ROC; gDepartment of Nursing, Hung Kuang University, Taichung, Taiwan, ROC; hDivision of Surgical Intensive Care Unit, Department of Intensive Care, Taichung Veterans General Hospital, Taichung, Taiwan, ROC  \nAbstract  \nBackground: Testicular cancer is the most common solid cancer diagnosed among young men. Despite good response to chemotherapy and a high survival rate, subsequent salvage therapies may still be required for some patients in advanced stages. The predictive and prognostic markers are crucial unmet needs.  \nMethods: We retrospectively analyzed advanced testicular cancer patients who had received first-line chemotherapy between January 2002 and December 2020. The associations between baseline characteristics and clinical outcomes were evaluated. Results: Of the 68 included patients, the median age was 29 years. Among them, 40 patients received only first-line chemotherapy while the remaining 28 received subsequent chemotherapy or surgeries. Data reveal that 82.5%(33/40) of the patients in the chemotherapy-only group were recorded as a good prognostic risk using the International Germ Cell Cancer Collaborative Group classification when compared with 35.7%(10/28) in the second-line therapy group. In the chemotherapy-only group, 53.8% of patients were presented with lymph node metastasis compared with 78.6% in the second-line therapy group (p = 0.068) . Fifteen percent of patients (6/40) were recorded as S stage 2–3 in the chemotherapy-only group, whereas 85.2%(23/28) were recorded as such in the second-line therapy group (p \u003C 0.001) . The 5-year overall survival estimation was 92.9% in the chemotherapy-only group and 77.3% in the second-line therapy group. Univariate analysis for overall survival revealed that those patients at the S 2–3 stage and those receiving second-line therapies showed a trend of having an increased death risk (hazard ratio [HR] = 8.26, 95% confidence interval (CI), 0.99-68.67, p = 0 .051; HR = 7.76, 95% CI, 0.93-64.99, p = 0 .059, respectively) . The S 2–3 stage was also independently associated with the risk of subsequent therapy (HR = 33. 13; 95% CI, 2.55-430.64, p = 0.007) .  \nConclusion: Our real-world data show the predictive role of serum tumor marker stage 2–3 to be associated with any subsequent therapies after first-line chemotherapy. This can facilitate clinical decision making during the testicular cancer treatment process. Keywords: Cisplatin; Non-seminomatous Germ Cell Tumor; Retroperitoneal Lymph Node Dissection; Seminoma  \n1. INTRODUCTION  \nTesticular cancer is the most common malignant solid tumor cancer seen among young men. According to the Cancer  \n* Address correspondence. Dr. Chi-Rei Yang, Department of Urology, China Medical University Hospital, 2, Yude Road, Taichung 404, Taiwan, ROC. E-mail [address: cryang036@gmail.com](address: cryang036@gmail.com) (C.-R. Yang); Dr. Jian-Ri Li, Division of Urology, Department of Surgery, Taichung Veterans General Hospital, 1650, Section 4, Taiwan Blvd, Taichung 407, Taiwan, [ROC. E-mail address: fisherfishli@yahoo.com](ROC. E-mail address: fisher","cbCaifUyE8hJPivv","https://ap.wps.com/l/cbCaifUyE8hJPivv","pdf",487877,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the study objective?\",\"answer\":\"To analyze risk factors for the need for subsequent (salvage) therapies after first-line chemotherapy in advanced testicular cancer patients.\"},{\"question\":\"How were patients selected and analyzed?\",\"answer\":\"Advanced testicular cancer patients who received first-line chemotherapy between January 2002 and December 2020 were retrospectively analyzed, assessing associations between baseline characteristics and clinical outcomes.\"},{\"question\":\"Which factor was independently associated with the risk of subsequent therapy?\",\"answer\":\"Serum tumor marker stage 2–3 showed an independent association with the risk of subsequent therapy (HR = 33.13, p = 0.007).\"},{\"question\":\"What do the results suggest for clinical decision-making?\",\"answer\":\"The predictive role of serum tumor marker stage 2–3 can facilitate clinical decision-making during testicular cancer treatment planning and follow-up.\"}]","Risk analysis of subsequent therapies after first-line chemotherapy in advanced testicular cancer patients | PDF",1790678318,18]